Leerink Partnrs Analysts Boost Earnings Estimates for TRVI

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Investment analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for Trevi Therapeutics in a report released on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($0.10) per share for the quarter, up from their previous estimate of ($0.13). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

Several other research firms have also recently commented on TRVI. HC Wainwright reaffirmed a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday. D. Boral Capital restated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday. Needham & Company LLC cut their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer lifted their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $6.47 on Friday. The business has a 50 day simple moving average of $4.60 and a 200 day simple moving average of $3.75. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The stock has a market capitalization of $497.32 million, a P/E ratio of -14.70 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01.

Insiders Place Their Bets

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TRVI. Point72 Asset Management L.P. purchased a new position in Trevi Therapeutics in the fourth quarter worth $17,099,000. Frazier Life Sciences Management L.P. raised its stake in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after buying an additional 3,283,684 shares during the period. Woodline Partners LP raised its stake in shares of Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after buying an additional 2,606,370 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Trevi Therapeutics in the fourth quarter valued at $10,300,000. Finally, Acorn Capital Advisors LLC bought a new stake in shares of Trevi Therapeutics in the fourth quarter valued at $8,244,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.